A novel gene risk score, informed by machine learning, predicted weight-loss outcomes after Roux-en-Y gastric bypass (RYGB) surgery, a new analysis showed.
Research presented at Digestive Disease Week 2025 is the first to show that the MyPhenome test can identify patients at risk for weight regain and those most likely to benefit from bariatric procedures.
The extensive body of research from Mayo Clinic emphasizes major advancements in obesity, including prediction of GLP-1 side effects, a new obesity sub-phenotype, and insights into personalized bariatric and endoscopic procedures.
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases.
Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA.
Respondents ages 18 to 65 highlight urgency for medical recognition, scientifically proven interventions, and genetic testing for personalized obesity treatment.
In this episode of Causes or Cures, Dr. Eeks chats with Dr. Andres Acosta MD PHD about the identification of 4 phenotypes for obesity and how they can revolutionize the future of obesity treatment.
